2010 Allosteric & Orthosteric Modulator Congress

 At Arrowhead’s 2010 Allosteric & Orthosteric Modulator Congress, presentations will highlight key developments in the field of allosteric and orthosteric modulator drug discovery and clinical development.

Our speakers will discuss key developments in the field, including the challenges facing researchers, the opportunities for pharma and recent successes in the field.

The following topics will be discussed throughout the conferences by a variety of speakers from the field:
*Allosteric regulation
*GPCRs
*Ion channels
*Kinases
*Transporters
*GABA receptors
*Approaches for allosteric and orthosteric modulation
*Screening technologies for allosteric and orthosteric modulators
*Therapeutic benefits

P. Jeffrey Conn, Ph.D., Director, Vanderbilt Program in Drug Discovery, Lee E. Limbird Professor of Pharmacology, Vanderbilt University Medical Center

Jean-Pierre Changeux, Ph.D., Professor, Institut Pasteur

Connie Sanchez, Ph.D., Vice President Neuroscience, Lundbeck Research USA

Prof. Dr. Klaus Mohr, Chairman, Pharmacology and Toxicology Section, Institute of Pharmacy, University of Bonn

Kenneth A. Jacobson, Ph.D., Acting Chief, Laboratory of Bioorganic Chemistry, National Institutes of Health

Kenneth Carlson, Ph.D., Senior Director, Biology, Ascent Therapeutics

Marlene A. Jacobson, Ph.D., Senior Investigator, Merck Research Labs

Eileen K. Jaffe, Ph.D., Senior Member, Professor, Fox Chase Cancer Center

Gilles Tamagnan, Ph.D., Head of Chemistry and Preclinical Research, Institute for Neurodegenerative Disorders & Molecular NeuroImaging, Yale University

Y. Gopi Shanker, Ph.D., Sr. Scientist, Neuroscience, Amgen

Jurgen Wess, Ph.D., Chief, Molecular Signaling Section, National Institutes of Health, NIDDK

Stefano Costanzi, Ph.D., Staff Scientist, Laboratory of Biological Modeling, National Institutes of Health, NIDDK